Clinical Trials in Switzerland / NCT05606523
Recruiting
Observational
Microbiota and Pancreatic Cancer Cachexia
NCT05606523 · tracked via the Priya Life Science Switzerland tracker
Condition(s) studied
Pancreatic CancerMicrobiotaCachexia
Study summary
This monocentric study aims at evaluating the effects of fecal microbiota transplantation from newly diagnosed cachectic and non-cachectic pancreatic cancer patients, and healthy volunteers on several cachexia-related parameters of germ-free mice.
Eligibility
Inclusion Criteria:
Patients with pancreatic cancer (n=12)
* ≥18 years and
* Newly diagnosed of pancreatic adenocarcinoma (local or metastatic) and
* Tube feeding or parenteral nutrition ≤ 14 days
Cachectic pancreatic cancer patients (n=6)
* Cachexia according to the Fearon criteria 1: involuntary weight loss \>5% over the last 6 months, or any level of weight loss \>2% and a BMI \<20 kg/m2 or sarcopenia. Sarcopenia will be diagnosed by BIA (fat-free mass index is \<17 kg/m2 in men and \<15 kg/m2 in women) 81, and not by CT, as it is faster and can be performed at the bedside of the patient. Non-cachectic pancreatic cancer patients (n=6)
* Normal nutritional state: weight stability (± 2% of habitual weight) over the last 6 months, no anorexia before the diagnosis (appetite rating on a visual analogue scale of 100mm), no known impaired glucose tolerance.
Healthy matched subjects (n=12)
* ≥18 years and
* BMI between 18.5 and 30 kg/m2 and
* Absence of chronic or acute disease and
* Matching for gender and age (± 5 years) with an included pancreatic cancer patient
Exclusion Criteria:
* \< 18 years or
* Inability to give consent or
* Insufficient knowledge of project language (French, German) or
* Pancreatic adenocarcinoma already treated by chemo- or radiotherapy, or major surgery as duodenopancreatectomy or biliary diversion
* Known rheumatologic or immunologic diseases
* Therapeutic antibiotics or immunosuppressive drugs (for instance glucocorticoids, cytostatics, antibodies) in the 30 days preceding the inclusion
Primary outcome measure(s)
- Body weight changes in mice after fecal material transplantation. — Between days 0 and 30
Body weight (g)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Geneva University Hospitals | Geneva | Switzerland | Recruiting |
Other trials for the same condition
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05606523 on ClinicalTrials.gov ↗ ← All trials in Switzerland